News

The latest on managing care, value-based care, insurance markets, payers & providers

Spending for health care per month per enrollee is 9% to 30% lower in Medicare Advantage (MA) than in traditional fee-for-service Medicare (TM), according to Vilsa Curto, of Harvard’s T.H. Chan School of Public Health, and colleagues from MIT and Stanford University. Their study, scheduled to…
There's a cloud in this morning’s silver lining of an article in the Wall Street Journal about many states feeling the love when it comes to revenue collections. It can be found in the article's second chart, the one titled:  “Enacted General-Fund Appropriations Changes for Some Areas.”…
One of the reasons the price for insulin has risen so dramatically in recent years, some experts claim, is because three companies—Eli Lilly, Novo Nordisk, and Sanofi Aventis—control 90% of the insulin market. FDA Commissioner Scott Gottlieb couldn’t agree more. He announced this week that the…
The FDA has granted orphan drug status to M7824 (Merck KGaA, Darmstadt, Germany) for the treatment of biliary tract cancer (BTC). M7824 is an investigational bifunctional immunotherapy that combines a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein. BTC, a group of rare and aggressive…
The FDA has granted orphan drug status to M7824 (Merck KGaA, Darmstadt, Germany) for the treatment of biliary tract cancer (BTC). M7824 is an investigational bifunctional immunotherapy that combines a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein. BTC, a group of rare and aggressive…
Mayo Clinic researchers have found that oxybutynin (Ditropan XL, Janssen Pharmaceuticals, Inc.) helps to reduce the frequency and intensity of hot flashes in women who are unable to take hormone replacement therapy, including breast cancer survivors. Hot flashes can be more severe in breast cancer survivors…
A study published in the Annals of Internal Medicine found that the infliximab biosimilar CT-P13 (Celltrion Inc.) demonstrated equivalent safety and efficacy to the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn’s disease in infliximab-naïve patients. TNF inhibitors, including…
Medical journals need to shore up their vetting process to detect physicians who write studies for them but who fail to report conflicts of interest with pharmaceutical and device manufacturers. A joint investigation by ProPublica and the New York Times also finds that the reporting system has not really…